Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

Completed · Phase 4

Conditions studied: Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity

In brief

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Key facts

Study ID

NCT05786521

Run by

The University of Texas Health Science Center at San Antonio

People needed

20

Starts

2023-04-01

Expected to finish

2024-05-20

Last updated by the study team

2025-05-04

Who can join

Age: 65 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Older than 65
• Have prediabetes or diabetes
• BMI ≥ 27.0 kg/m2
• Living independently (not in assisted living or nursing home)

You may not qualify if…

• Have heart disease
• Have liver disease
• Smoke

Where it is running

• UT Health San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.